Drug Profile
AR 101
Alternative Names: AR-101-Aimmune-Therapeutics; AR101; Arachis hypogaea Allergen Powder-dnfp; Characterised-peanut-allergen-oral-immunotherapy-ARC; CPNA-Aimmune-Therapeutics; defatted powder of Arachis hypogaea L; PALFORZIA; Peanut (Arachis hypogaea) allergaen powder-dnfp; Peanut Allergen Powder-dnfp; Peanut allergy immunotherapy - Aimmune Therapeutics; Peanut allergy OIT - Aimmune Therapeutics; semen; semen (peanuts)Latest Information Update: 23 Nov 2023
Price :
$50
*
At a glance
- Originator Allergen Research Corporation
- Developer Aimmune Therapeutics; Regeneron Pharmaceuticals; Sanofi
- Class Allergens; Antiallergics; Food allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Peanut hypersensitivity
Most Recent Events
- 20 Nov 2023 Positive adverse events data from a phase III POSEIDON trial in Peanut hypersensitivity (In adolescents, In children) released by Stallergenes Greer
- 04 Sep 2023 Stallergen acquires AR 101 from Nestle helath Sciences
- 27 Apr 2023 Aimmune Therapeutics completes a phase III ARC008 trial for Peanut hypersensitivity (In children, In adolescents, In adults) in USA, France, Canada, Denmark, Germany, Ireland, Italy, Netherlands, Spain, Sweden and United Kingdom (PO) (NCT03292484) (EudraCT2017-001334-26)